Skip to content
WeighLab
Menu
Ranked #376 · Grade C

Mevo Health review

Mevo Health is a direct-pay telemedicine platform selling compounded semaglutide ('as low as $199') and tirzepatide ('as low as $259') under named Medical Director Dr. David Wasef, head of the Mevo Provider Network.

Visit Mevo Health Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$199/mo (starting dose, compounded)
Tirzepatide
$259/mo (starting dose, quarterly plan, compounded)
Coverage
Coverage not published
Brand-name
Compounded only

Semaglutide · modeled / year

$2,388

Tirzepatide · modeled / year

$3,108

Pricing verified August 2026

The Index scorecard

Mevo Health scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month47/100
Price Transparency78/100
Nationwide Access24/100
Formulation Options77/100
Clinical Oversight68/100
Contract Flexibility20/100

Where the value is

  • Named, board-certified Medical Director (Dr. David Wasef) heading a stated provider network
  • LegitScript verification badge displayed
  • Publishes the FDA compounded-medication disclaimer verbatim
  • Cancel-anytime language ('cancel before the next billing cycle') suggests no long lock-in beyond the billing period chosen

The tradeoffs

  • The advertised 'as low as $199' / 'as low as $259' floors sit next to monthly/quarterly/six-month plan options with no page clarifying which term unlocks the low price
  • No pharmacy partner named — only unlabeled '503A U.S. compounding pharmacy' logos, not independently re-confirmed here
  • No states-served list found on any page reached
  • /pricing and /weight-loss subpages both 404, so no per-dose breakdown could be verified beyond the single homepage floor figure

The bottom line

Best for: Cost-first shoppers who want a named physician-led provider network, if the quarterly/six-month prepay needed to hit the advertised floor price works for you. Mevo Health is a direct-pay telemedicine platform selling compounded semaglutide ('as low as $199') and tirzepatide ('as low as $259') under named Medical Director Dr. David Wasef, head of the Mevo Provider Network.

Ranked #376 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Mevo Health.

The 18 programs nearest this one

Pricing, states and verification reflect Mevo Health's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Mevo Health's site. Not medical advice; see our disclosure.

← Back to the value leaderboard